Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Ubiquitin–proteasome system and Parkinson's disease

Identifieur interne : 003138 ( Main/Exploration ); précédent : 003137; suivant : 003139

Ubiquitin–proteasome system and Parkinson's disease

Auteurs : C. Warren Olanow [États-Unis] ; Kevin St. P. Mcnaught [États-Unis]

Source :

RBID : ISTEX:57BF90C0AACEB88C954E99CBB94BAAC6F18F5FD4

Descripteurs français

English descriptors

Abstract

Increasing genetic, pathological, and experimental evidence suggest that neurodegeneration in both familial and sporadic forms of Parkinson's disease (PD) may be related to a defect in the capacity of the ubiquitin–proteasome system (UPS) to clear unwanted proteins, resulting in protein accumulation, aggregation, and cytotoxicity. This concept is supported by in vitro and in vivo laboratory experiments which show that inhibition of UPS function can cause neurodegeneration coupled with the formation of Lewy body–like inclusions. This hypothesis could account for the presence of protein aggregates and Lewy bodies in PD, the other biochemical features seen in the disorder, and the age‐related vulnerability of the substantia nigra pars compacta. It also suggests novel targets for putative neuroprotective therapies for PD. © 2006 Movement Disorder Society

Url:
DOI: 10.1002/mds.21013


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Ubiquitin–proteasome system and Parkinson's disease</title>
<author>
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</author>
<author>
<name sortKey="Mcnaught, Kevin St P" sort="Mcnaught, Kevin St P" uniqKey="Mcnaught K" first="Kevin St. P." last="Mcnaught">Kevin St. P. Mcnaught</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:57BF90C0AACEB88C954E99CBB94BAAC6F18F5FD4</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.21013</idno>
<idno type="url">https://api.istex.fr/document/57BF90C0AACEB88C954E99CBB94BAAC6F18F5FD4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001214</idno>
<idno type="wicri:Area/Istex/Curation">001214</idno>
<idno type="wicri:Area/Istex/Checkpoint">001B97</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Olanow C:ubiquitin:proteasome:system</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16972273</idno>
<idno type="wicri:Area/PubMed/Corpus">002A98</idno>
<idno type="wicri:Area/PubMed/Curation">002A98</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002A46</idno>
<idno type="wicri:Area/Ncbi/Merge">001841</idno>
<idno type="wicri:Area/Ncbi/Curation">001841</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001841</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Olanow C:ubiquitin:proteasome:system</idno>
<idno type="wicri:Area/Main/Merge">004451</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:07-0021705</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001926</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001395</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001860</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Olanow C:ubiquitin:proteasome:system</idno>
<idno type="wicri:Area/Main/Merge">004955</idno>
<idno type="wicri:Area/Main/Curation">003138</idno>
<idno type="wicri:Area/Main/Exploration">003138</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Ubiquitin–proteasome system and Parkinson's disease</title>
<author>
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mcnaught, Kevin St P" sort="Mcnaught, Kevin St P" uniqKey="Mcnaught K" first="Kevin St. P." last="Mcnaught">Kevin St. P. Mcnaught</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mount Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-11">2006-11</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1806">1806</biblScope>
<biblScope unit="page" to="1823">1823</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">57BF90C0AACEB88C954E99CBB94BAAC6F18F5FD4</idno>
<idno type="DOI">10.1002/mds.21013</idno>
<idno type="ArticleID">MDS21013</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Age Factors</term>
<term>Animals</term>
<term>Central Nervous System (metabolism)</term>
<term>Humans</term>
<term>Models, Biological</term>
<term>Multicatalytic endopeptidase complex</term>
<term>Mutation</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (genetics)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Proteasome Endopeptidase Complex (genetics)</term>
<term>Proteasome Endopeptidase Complex (metabolism)</term>
<term>Protein</term>
<term>Ubiquitin</term>
<term>Ubiquitin (genetics)</term>
<term>Ubiquitin (metabolism)</term>
<term>alpha‐synuclein</term>
<term>proteasome</term>
<term>protein accumulation</term>
<term>ubiquitin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Proteasome Endopeptidase Complex</term>
<term>Ubiquitin</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Central Nervous System</term>
<term>Parkinson Disease</term>
<term>Proteasome Endopeptidase Complex</term>
<term>Ubiquitin</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Age Factors</term>
<term>Animals</term>
<term>Humans</term>
<term>Models, Biological</term>
<term>Mutation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Multicatalytic endopeptidase complex</term>
<term>Parkinson maladie</term>
<term>Protéine</term>
<term>Système nerveux pathologie</term>
<term>Ubiquitine</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Increasing genetic, pathological, and experimental evidence suggest that neurodegeneration in both familial and sporadic forms of Parkinson's disease (PD) may be related to a defect in the capacity of the ubiquitin–proteasome system (UPS) to clear unwanted proteins, resulting in protein accumulation, aggregation, and cytotoxicity. This concept is supported by in vitro and in vivo laboratory experiments which show that inhibition of UPS function can cause neurodegeneration coupled with the formation of Lewy body–like inclusions. This hypothesis could account for the presence of protein aggregates and Lewy bodies in PD, the other biochemical features seen in the disorder, and the age‐related vulnerability of the substantia nigra pars compacta. It also suggests novel targets for putative neuroprotective therapies for PD. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>État de New York</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="État de New York">
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</region>
<name sortKey="Mcnaught, Kevin St P" sort="Mcnaught, Kevin St P" uniqKey="Mcnaught K" first="Kevin St. P." last="Mcnaught">Kevin St. P. Mcnaught</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003138 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003138 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:57BF90C0AACEB88C954E99CBB94BAAC6F18F5FD4
   |texte=   Ubiquitin–proteasome system and Parkinson's disease
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024